Avidity Biosciences (RNA) CHRO auto-sells shares in RSU tax sell-to-cover

Rhea-AI Filing Summary

Avidity Biosciences’ Chief Human Resources Officer Teresa McCarthy reported automatic share sales tied to RSU vesting. On January 21, 2026, she sold 1,476 shares of Avidity Biosciences common stock at $72.45 per share, leaving her with 115,391 shares directly owned. A second sale the same day covered 1,453 shares at $72.45 per share, after which she directly held 113,938 shares.

According to the footnote, these transactions were required to cover tax withholding obligations from restricted stock units that vested on January 20, 2026. The issuer mandates a “sell-to-cover” method under its equity incentive plans, so these sales were not discretionary trades by McCarthy. She also executed an instruction letter intended to satisfy the affirmative defense conditions of Rule 10b5-1, meaning the sales followed a pre-established automatic trading instruction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCarthy Teresa

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

3020 CALLAN RD.

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		S		1,476(1)	D	$72.45	115,391	D
Common Stock	01/21/2026		S		1,453(1)	D	$72.45	113,938	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 20, 2026 and the sale of the resulting shares of common stock on January 21, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Avidity Biosciences (RNA) report for Teresa McCarthy?

Avidity Biosciences reported that Chief Human Resources Officer Teresa McCarthy sold shares of common stock on January 21, 2026 in two separate transactions, each reported as a sale of non-derivative securities.

How many Avidity Biosciences (RNA) shares did Teresa McCarthy sell and at what price?

Teresa McCarthy sold 1,476 shares of Avidity Biosciences common stock at $72.45 per share in one transaction and 1,453 shares at $72.45 per share in a second transaction on January 21, 2026.

How many Avidity Biosciences (RNA) shares does Teresa McCarthy own after these transactions?

After the first reported sale, Teresa McCarthy directly owned 115,391 shares of Avidity Biosciences common stock. After the second reported sale, she directly owned 113,938 shares.

Were Teresa McCarthy’s Avidity Biosciences (RNA) share sales discretionary trades?

No. The footnote explains that the sales represent shares required to be sold to cover tax withholding obligations related to RSUs that vested on January 20, 2026. The issuer’s equity incentive plans mandate a “sell-to-cover” transaction, so these are not discretionary trades by McCarthy.

What is the purpose of the Rule 10b5-1 reference in Teresa McCarthy’s Avidity Biosciences (RNA) filing?

The filing states that Teresa McCarthy executed an instruction letter for the automatic sale of the “sell-to-cover” shares, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1. This indicates the sales followed a pre-established automatic trading instruction.

What position does Teresa McCarthy hold at Avidity Biosciences (RNA)?

Teresa McCarthy is the Chief Human Resources Officer of Avidity Biosciences, and she is identified as an officer of the company in the Form 4.